Sotera Health Company is a global provider of end-to-end sterilization solutions, laboratory testing, and advisory services for the healthcare industry. The company operates through three primary business segments: Sterigenics, which offers outsourced terminal sterilization and irradiation services using gamma, ethylene oxide, and electron beam technologies for medical devices, pharmaceuticals, and food products; Nordion, which supplies Cobalt-60 sources and medical gamma technologies for sterilization and cancer treatment; and Nelson Labs, which provides microbiological and analytical chemistry testing and regulatory compliance consulting. Sotera Health serves customers in multiple countries, including major medical device and pharmaceutical manufacturers, supporting their regulatory compliance and product safety requirements. The company’s services are integral to the manufacturing processes and supply chains of healthcare products, ensuring sterility and safety for patients and healthcare practitioners worldwide.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Health Information Services Homepage soterahealth.com
Sector Healthcare IR page investors.soterahealth.com
Tags
sterilization services, gamma irradiation, ethylene oxide processing, electron beam irradiation, cobalt-60 supply, microbiological testing, analytical chemistry, regulatory compliance, medical device testing, pharmaceutical testing, food safety, lab services, Sterigenics, Nordion, Nelson Labs, Regulatory Compliance Associates
Press page —

Metrics

Valuation  
Market cap $ 5.281B
Market cap (USD) $ 5.281B
P/E 30.82
PEG —
P/BV 7.20
P/S 4.29
P/OCF 15.93
P/FCF 39.00
Dividend yield —
Turnover / mcap —
Returns  
ROE 15.4%
ROI 2.8%
ROIC 7.0%
Profit margin 6.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 291.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 1.164B 1.1B 1.049B 1.004B 931.478M 818.158M
Net profit 77.949M 44.398M 51.376M -233.57M 116.882M -38.617M
Free cash flow 149.177M 45.094M -362.707M 95.583M 179.383M 67.078M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 17.64 13.68 16.85 8.33 23.55 27.44
Price performance 12m 0.29 -0.19 1.02 -0.65 -0.14 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 91.7M 108M 118M 148M 140M 139M
↳ YoY growth +17.9% +9.5% +24.7% -5.0% -0.7%
↳ 5y CAGR +8.7%
Borrowings, current (USD) — — 0.00 0.00 197M 4.8M 14.8M 14M
Borrowings, non-current (USD) — — 1.82B 1.74B 1.75B 2.22B 2.21B 2.13B
Lease liabilities (USD) — — 84.4M 84.3M 87.8M 98.6M 128M 133M
Cash and deposits (USD) 96.8M 63M 102M 107M 395M 296M 277M 345M
Intangible assets (USD) — — 643M 599M 491M 416M 318M 288M
Right-of-use assets (USD) — — 46M 39.9M 26.5M 24M 27.6M 33.4M
Net debt (borrowings + leases - cash) (USD) — — 1.81B 1.72B 1.64B 2.03B 2.07B 1.93B
Cash flow detail
Operating cash flow (USD) — 149M 121M 282M 278M -148M 224M 287M
Purchases of property, plant and equipment (USD) — -57.3M -53.5M -102M -182M -215M -179M -138M
Change in receivables (cash effect) (USD) — 11.8M 1.94M -15.5M -12.6M -21.7M 2.22M 7.15M
Change in inventories (cash effect) (USD) — -282,000 3.78M -20.2M 14.4M -9.97M -4.75M -2.38M
Change in payables (cash effect) (USD) — -8.97M -6.02M 19.8M 1.11M -5.33M -6.64M 5.19M
Dividends paid (cash effect) (USD) — -691M 0.00 0.00 — — — —
Share buybacks (cash effect) (USD) — 0.00 -34M 0.00 0.00 — — —
Interest paid (cash effect) (USD) — -151M -211M -58.8M -75.8M -174M -180M -164M
Income taxes paid (cash effect) (USD) — -44.6M -24M -52M -75.5M -50.2M -65.8M -60.9M
Share-based compensation (USD) — 6.88M 11M 13.9M 21.2M 32.2M 36.8M 30.9M
Operating cash flow before change in receivables (USD) — 137M 119M 297M 291M -126M 222M 280M
Free cash flow (OCF - PPE - intangibles) (USD) — 91.8M 67.1M 179M 95.6M -363M 45.1M 149M
Income detail
Total comprehensive income (USD) — -4.97M -37.2M 128M -257M 65.3M -71.2M 176M
Comprehensive income to owners (USD) — -5.28M -38.1M 127M -257M 65.3M -71.2M 176M
Reported Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Nov 2, 2022 Feb 28, 2023 Feb 27, 2024 Feb 27, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis(1), compared to Q3 2025

•Q3 2026 net income of $58 million or $0.20 per diluted share

•Q3 2026 Adjusted EBITDA(1) increased 3.9%, or 4.0% on a constant currency basis

•Q3 2026 Adjusted EPS(1) of $0.29, an increase of 12% per diluted share

•Reaffirming full-year 2026 net revenues growth outlook of 5.25% - 6.75% and Adjusted EBITDA growth outlook of 5.75% - 7.25%, both on a constant currency basis

CLEVELAND, OH, November 3, 2026 – Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and nine-months ended September 30, 2026.

“We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion,” said Alton Shader, Chief Executive Officer.

Oct 21, 2026

Download PDF

CLEVELAND, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the third quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating and financial results.

A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health. A replay of the webcast will be available later in the day on November 3.

Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.

About Sotera Health Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

| Contacts | |

| Jason Peterson Vice President, Investor Relations [email protected] | |

| | |

| Kristin Gibbs Chief Marketing Officer, Sotera Health [email protected] | |

Source: Sotera Health Company

On August 11, 2026, James C. Neary notified the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) of his resignation as a Class I director, effective August 13, 2026 (the “Effective Date”). Mr. Neary’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. In connection with Mr. Neary’s resignation, the Board fixed the size of the Board at eleven directors as of the Effective Date.

Prompts

Sotera Health Company (ticker SHC), listed in United States.

Company History

Date Change Detail
Sep 30, 2020 Renamed Sotera Health Topco, Inc. → SOTERA HEALTH CO

ETFs Holding Sotera Health Company

ETF Weight in ETF Shares Market value As of
BSMC 1.12% 105,095 $ 1.865M Jun 30, 2026
AIVL 0.55% 128,472 $ 2.28M Jun 30, 2026
FEMV 0.23% 695 $ 12.336K Jun 30, 2026
AVSC 0.23% 454,080 $ 7.379M Nov 16, 2026
CDX short -0.19% -29,731.0149 $ -477.183K Nov 17, 2026
DFAS 0.09% 1,947,787 $ 31.749M Nov 12, 2026
EBI 0.08% 31,132 $ 588.395K Aug 31, 2026
MSSM 0.04% 15,055 $ 284.54K Aug 31, 2026
DXUV 0.03% 131,992 $ 2.151M Nov 12, 2026
DFAC 0.02% 1,084,696 $ 17.681M Nov 12, 2026
DCOR 0.01% 362,392 $ 5.907M Nov 12, 2026
FMDE 0.01% 42,808 $ 759.842K Jun 30, 2026
AVSU 0.01% 1,549 $ 25.171K Nov 16, 2026
DFAU 0.01% 73,478 $ 1.198M Nov 12, 2026
DFUS 0.01% 85,873 $ 1.4M Nov 12, 2026
MSLC 0.00% 2,353 $ 44.472K Aug 31, 2026
AVUS 0.00% 42,011 $ 682.679K Nov 16, 2026